Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 3—March 2019

University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018

Heidi M. SoetersComments to Author , Lucy A. McNamara, Amy E. Blain, Melissa Whaley, Jessica R. MacNeil, Susan Hariri, Sarah A. Mbaeyi, and for the Serogroup B Meningococcal Disease University Outbreak Group
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 2

Vaccination response to university-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013–2018*

State of university
Primary MenB vaccine
Vaccination strategy
Vaccination coverage
Cases after vaccine implementation
New Jersey MenB-4C† Mass vaccination campaign Dose 1, 95%; dose 2, 89% 1
California MenB-4C† Mass vaccination campaign Dose 1, 51%; dose 2, 40% 0
Rhode Island MenB-FHbp Mass vaccination campaign Dose 1, 94%; dose 2, 80%; dose 3, 77%‡ 0
Oregon MenB-FHbp§ Mass vaccination campaigns; student health; local pharmacies Dose 1, 52%; dose 2, 40%; dose 3, 10%
California MenB-4C Mass vaccination campaign Dose 1, 90%; dose 2, 90%# 0
New Jersey MenB-FHbp Local providers/pharmacies; student health; some vaccination campaigns NA 0
Wisconsin MenB-4C Mass vaccination campaign Dose 1, 67%; dose 2, >31%**
Oregon MenB-4C Mass vaccination campaign with targeted student groups; vaccine requirement Dose 1, 98%; dose 2, 93% 2
Massachusetts†† MenB-4C Mass vaccination campaign; student health; providers/pharmacies Dose 1, 34%**,‡‡; dose 2, 16% 1
Pennsylvania MenB-4C Vaccinated athletic team; campus-wide recommendation for vaccination at student health Dose 1, 14%; dose 2, 2%** 0

*MenB, serogroup B meningococcal; MenB-4C, Bexsero (GlaxoSmithKline,; MenB-FHbp, Trumenba (Pfizer,; NA, vaccination coverage estimates not available.
†Vaccine available through a CDC-sponsored investigational new drug protocol.
‡Coverage data refer to 2015 campaign. Incoming freshmen and returning study abroad students were also vaccinated in 2015–2016.
§MenB-4C was also used in response to this outbreak; 21% of students completed either vaccine series. Presented coverage data for this university are as of July 2018.
¶One case in each of these outbreaks occurred 6 days after MenB vaccination efforts commenced, thus prior to any expected immunity.
#This coverage estimate represents the number of persons vaccinated in the second campaign, which likely included some first doses.
**Reported coverage reflects only vaccine doses given on campus; additional students received vaccine doses from providers or pharmacies at home or in other states.
††Cases occurred at 2 universities in a college consortium in the same geographic area. The first 2 cases occurred at university 1 and the third case occurred at university 2. Both universities began vaccination efforts following the second case.
‡‡Combined first-dose coverage data for both universities are presented in the table. First-dose coverage was 33% at university 1 (23,388 undergraduates) and 41% at university 2 (2,500 undergraduates) (Figure 2). Vaccination was ongoing at the time of publication; therefore, data should be considered preliminary.

Main Article

1Members of the group are listed at the end of this article.

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.